These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10666411)

  • 1. Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes.
    Gilbert RE; Rumble JR; Cao Z; Cox AJ; van Eeden P; Allen TJ; Kelly DJ; Cooper ME
    Circ Res; 2000 Feb; 86(2):158-65. PubMed ID: 10666411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes.
    Bonnet F; Cao Z; Cooper ME; Cox AJ; Kelly DJ; Gilbert RE
    Diabetes Metab; 2003 Sep; 29(4 Pt 1):386-92. PubMed ID: 14526266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular mechanisms of diabetic vascular hypertrophy.
    Vranes D; Cooper ME; Dilley RJ
    Microvasc Res; 1999 Jan; 57(1):8-18. PubMed ID: 9882558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPARC gene expression is increased in diabetes-related mesenteric vascular hypertrophy.
    Jandeleit-Dahm K; Rumble J; Cox AJ; Kelly DJ; Dziadek M; Cooper ME; Gilbert RE
    Microvasc Res; 2000 Jan; 59(1):61-71. PubMed ID: 10625572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products.
    Rumble JR; Cooper ME; Soulis T; Cox A; Wu L; Youssef S; Jasik M; Jerums G; Gilbert RE
    J Clin Invest; 1997 Mar; 99(5):1016-27. PubMed ID: 9062360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes.
    Jones SE; Gilbert RE; Kelly DJ
    J Diabetes Complications; 2004; 18(5):309-15. PubMed ID: 15337505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term endothelin receptor blockade improves cardiovascular function in diabetes.
    Verma S; Arikawa E; McNeill JH
    Am J Hypertens; 2001 Jul; 14(7 Pt 1):679-87. PubMed ID: 11465653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats.
    Evans T; Deng DX; Chen S; Chakrabarti S
    Diabetes; 2000 Apr; 49(4):662-6. PubMed ID: 10871206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies.
    Cooper ME; Cao Z; Rumble JR; Jandeleit K; Allen TJ; Gilbert RE
    Metabolism; 1998 Dec; 47(12 Suppl 1):24-7. PubMed ID: 9867067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist.
    Kaddoura S; Firth JD; Boheler KR; Sugden PH; Poole-Wilson PA
    Circulation; 1996 Jun; 93(11):2068-79. PubMed ID: 8640984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of endothelin receptor blockade on hypervasoreactivity in streptozotocin-diabetic rats: vessel-specific involvement of thromboxane A2.
    Arikawa E; Cheung C; Sekirov I; Battell ML; Yuen VG; McNeill JH
    Can J Physiol Pharmacol; 2006; 84(8-9):823-33. PubMed ID: 17111027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nonselective endothelin-1 receptor antagonism on cardiac mast cell-mediated ventricular remodeling in rats.
    Murray DB; Gardner JD; Brower GL; Janicki JS
    Am J Physiol Heart Circ Physiol; 2008 Mar; 294(3):H1251-7. PubMed ID: 18178727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic endothelin antagonism restores cerebrovascular function in diabetes.
    Dumont AS; Dumont RJ; McNeill JH; Kassell NF; Sutherland GR; Verma S
    Neurosurgery; 2003 Mar; 52(3):653-60; discussion 659-60. PubMed ID: 12590691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats.
    Schiffrin EL; Sventek P; Li JS; Turgeon A; Reudelhuber T
    Br J Pharmacol; 1995 Aug; 115(8):1377-81. PubMed ID: 8564194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes.
    Sachidanandam K; Portik-Dobos V; Kelly-Cobbs AI; Ergul A
    Can J Physiol Pharmacol; 2010 Jun; 88(6):616-21. PubMed ID: 20628426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition.
    Cooper ME; Rumble J; Komers R; Du HC; Jandeleit K; Chou ST
    Diabetes; 1994 Oct; 43(10):1221-8. PubMed ID: 7926292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats.
    Li JS; Schürch W; Schiffrin EL
    Am J Hypertens; 1996 Aug; 9(8):803-11. PubMed ID: 8862227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model.
    Dhein S; Hochreuther S; Aus Dem Spring C; Bollig K; Hufnagel C; Raschack M
    J Pharmacol Exp Ther; 2000 May; 293(2):351-9. PubMed ID: 10773002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes-induced vascular dysfunction in the retina: role of endothelins.
    Deng D; Evans T; Mukherjee K; Downey D; Chakrabarti S
    Diabetologia; 1999 Oct; 42(10):1228-34. PubMed ID: 10525664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control.
    Abdelsaid M; Kaczmarek J; Coucha M; Ergul A
    Life Sci; 2014 Nov; 118(2):268-73. PubMed ID: 24447630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.